Customizing chemotherapy for colon cancer: The potential of gene expression profiling

Drug Resistance Updates

Volumn 7, Issue 3, 2004, Pages 209-218

  Mariadason, John M ^a   Arango, Diego ^b   Augenlicht, Leonard H ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b BIOMEDICUM HELSINKI   (Finland)

Author keywords

5 FU; Colon cancer; Gene expression profiling; Microarray

Indexed keywords

BUTYRIC ACID; CAMPTOTHECIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DNA MICROARRAY; DRUG MECHANISM; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENE INDUCTION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; XENOGRAFT;

EID: 3543096870     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2004.05.001     Document Type: Article

References (109)

1. Agrawal D., Chen T., Irby R., Quackenbush J., Chambers A.F., Szabo M., Cantor A., Coppola D., Yeatman T.J. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl. Cancer Inst. 94:2002;513-521
2. Agrawal D., Chen T., Irby R., Quackenbush J., Chambers A.F., Szabo M., Cantor A., Coppola D., Yeatman T.J. Osteopontin identified as colon cancer tumor progression marker. C. R. Biol. 326:2003;1041-1043
3. Ahnen D.J., Feigl P., Quan G., Fenoglio-Preiser C., Lovato L.C., Bunn P.A. Jr., et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 58:1998;1149-1158
4. Allegra C.J., Paik S., Colangelo L.H., Parr A.L., Kirsch I., Kim G., Klein P., Johnston P.G., Wolmark N., Wieand H.S. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J. Clin. Oncol. 21:2003;241-250
5. Alon U., Barkai N., Notterman D.A., Gish K., Ybarra S., Mack D., Levine A.J. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl. Acad. Sci. USA. 96:1999;6745-6750
6. Arango D., Corner G.A., Wadler S., Catalano P.J., Augenlicht L.H. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res. 61:2001;4910-4915
7. Arango D., Mariadason J.M., Wilson A.J., Yang W., Corner G.A., Nicholas C., Aranes M.J., Augenlicht L.H. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br. J. Cancer. 89:2003;1757-1765
8. Augenlicht L.H., Taylor J., Anderson L., Lipkin M. Patterns of gene expression that characterize the colonic mucosa in patients at genetic risk for colonic cancer. Proc. Natl. Acad. Sci. USA. 88:1991;3286-3289
9. Augenlicht L.H., Wadler S., Corner G., Richards C., Ryan L., Multani A.S., Pathak S., Benson A., Haller D., Heerdt B.G. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res. 57:1997;1769-1775
10. Augenlicht L.H., Wahrman M.Z., Halsey H., Anderson L., Taylor J., Lipkin M. Expression of cloned sequences in biopsies of human colonic tissue and in colonic carcinoma cells induced to differentiate in vitro. Cancer Res. 47:1987;6017-6021
11. Barratt P.L., Seymour M.T., Stenning S.P., Georgiades I., Walker C., Birbeck K., Quirke P. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet. 360:2002;1381-1391
12. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8:2002;816-824
13. Benhattar J., Cerottini J.P., Saraga E., Metthez G., Givel J.C. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int. J. Cancer. 69:1996;190-192
14. Berglund A., Edler D., Molin D., Nordlinder H., Graf W., Glimelius B. Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma. Anticancer Res. 22:2002;3653-3659
15. Bertucci F., Salas S., Eysteries S., Nasser V., Finetti P., Ginestier C., et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene. 23:2004;1377-1391
16. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA. 98:2001;13790-13795
17. Birkenkamp-Demtroder K., Christensen L.L., Olesen S.H., Frederiksen C.M., Laiho P., Aaltonen L.A., et al. Gene expression in colorectal cancer. Cancer Res. 62:2002;4352-4363
18. Boon K., Caron H.N., van Asperen R., Valentijn L., Hermus M.C., van Sluis P., et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 20:2001;1383-1393
19. Boussioutas A., Li H., Liu J., Waring P., Lade S., Holloway A.J., Taupin D., Gorringe K., Haviv I., Desmond P.V., Bowtell D.D. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res. 63:2003;2569-2577
20. Brazma A., Hingamp P., Quackenbush J., Sherlock G., Spellman P., Stoeckert C., et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29:2001;365-371
21. Bullinger L., Dohner K., Bair E., Frohling S., Schlenk R.F., Tibshirani R., Dohner H., Pollack J.R. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350:2004;1605-1616
22. Cai W.W., Mao J.H., Chow C.W., Damani S., Balmain A., Bradley A. Genome-wide detection of chromosomal imbalances in tumors using BAC microarrays. Nat. Biotechnol. 20:2002;393-396
23. Clarke P.A., George M.L., Easdale S., Cunningham D., Swift R.I., Hill M.E., Tait D.M., Workman P. Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. Cancer Res. 63:2003;6855-6863
24. Coller H.A., Grandori C., Tamayo P., Colbert T., Lander E.S., Eisenman R.N., Golub T.R. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. USA. 97:2000;3260-3265
25. Compton, C.C., 2002. Surgical pathology of colorectal cancer. Humana Press, Totowa, New Jersey.
26. Conti J.A., Kemeny N.E., Saltz L.B., Huang Y., Tong W.P., Chou T.C., Sun M., Pulliam S., Gonzalez C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol. 14:1996;709-715
27. Coudry R., Meireles S., Stoyanova R., Carpino A., Cooper H.A., Engstrom P.F., Clapper M.L. Gene expression profiling of formalin-fixed, paraffin-embedded archival tissue following laser capture microdissection. Proc. Am. Assoc. Cancer Res. 45:2004;LB-79. Abstract
28. Crnogorac-Jurcevic T., Efthimiou E., Nielsen T., Loader J., Terris B., Stamp G., et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene. 21:2002;4587-4594
29. Cvitkovic E., Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin. Oncol. 26:1999;647-662
30. Dan S., Tsunoda T., Kitahara O., Yanagawa R., Zembutsu H., Katagiri T., Yamazaki K., Nakamura Y., Yamori T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 62:2002;1139-1147
31. Dannenberg, P.V., 2002. Molecular markers of chemotherapy resistance in colorectal cancer. Humana Press, Totowa, New Jersey.
32. de Gramont A., Vignoud J., Tournigand C., Louvet C., Andre T., Varette C., et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-h continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer. 33:1997;214-219
33. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Delineation of prognostic biomarkers in prostate cancer. Nature. 412:2001;822-826
34. Ding L., Chu S., Kunitake S., MacNair J., Cheung E., Ghosh M., et al. Gene expression profiling of microdissected human breast cancer cells from formalin-fixed paraffin-embedded sections using microarrays. Proc. Am. Assoc. Cancer Res. 45:2004;LB-142. Abstract
35. Dong S., Wang E., Hsie L., Cao Y., Chen X., Gingeras T.R. Flexible use of high-density oligonucleotide arrays for single-nucleotide polymorphism discovery and validation. Genome Res. 11:2001;1418-1424
36. Elsaleh H., Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin. Colorectal Cancer. 1:2001a;104-109
37. Elsaleh H., Joseph D., Grieu F., Zeps N., Spry N., Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 355:2000;1745-1750
38. Elsaleh H., Powell B., McCaul K., Grieu F., Grant R., Joseph D., Iacopetta B. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin. Cancer Res. 7:2001b;1343-1349
39. Erlander M.G., Ellis M.J., Olson J., Wittliff J.L., Smith B., Younger J., Sgroi D.C. Global gene expression profiling from formalin-fixed paraffin-embedded (FFPE) tissues Implications for retrospective and prospective clinical studies. Proc. Am. Soc. Clin. Oncol. 22:2003;125. Abstract 498
40. Femino A.M., Fay F.S., Fogarty K., Singer R.H. Visualization of single RNA transcripts in situ. Science. 280:1998;585-590
41. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Case history: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3:2004;391-400
42. Findlay M.P., Cunningham D., Morgan G., Clinton S., Hardcastle A., Aherne G.W. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br. J. Cancer. 75:1997;903-909
43. Fodde R., Smits R., Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer. 1:2001;55-67
44. Frederiksen C.M., Knudsen S., Laurberg S., Orntoft T.F. Classification of Dukes' B and C colorectal cancers using expression arrays. J. Cancer Res. Clin. Oncol. 129:2003;263-271
45. Gillespie J.W., Ahram M., Best C.J., Swalwell J.I., Krizman D.B., Petricoin E.F., Liotta L.A., Emmert-Buck M.R. The role of tissue microdissection in cancer research. Cancer J. 7:2001;32-39
46. Gitan R.S., Shi H., Chen C.M., Yan P.S., Huang T.H. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res. 12:2002;158-164
47. Goh H.S., Yao J., Smith D.R. p53 point mutation and survival in colorectal cancer patients. Cancer Res. 55:1995;5217-5221
48. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 286:1999;531-537
49. Grem J.L., Danenberg K.D., Behan K., Parr A., Young L., Danenberg P.V., Nguyen D., Drake J., Monks A., Allegra C.J. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Clin. Cancer Res. 7:2001;999-1009
50. Hanash S. Disease proteomics. Nature. 422:2003;226-232
51. Herman J.G., Merlo A., Mao L., Lapidus R.G., Issa J.P., Davidson N.E., Sidransky D., Baylin S.B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:1995;4525-4530
52. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53
53. Hwang P.M., Bunz F., Yu J., Rago C., Chan T.A., Murphy M.P., et al. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat. Med. 7:2001;1111-1117
54. Iacopetta B., Elsaleh H., Zeps N. Microsatellite instability in colon cancer. N. Engl. J. Med. 349:2003;1774-1776. author reply 1774-1776
55. Ishkanian A.S., Malloff C.A., Watson S.K., DeLeeuw R.J., Chi B., Coe B.P., et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat. Genet. 36:2004;299-303
56. Johnston P.G., Benson A.B. 3rd, Catalano P., Rao M.S., O'Dwyer P.J., Allegra C.J. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J. Clin. Oncol. 21:2003;815-819
57. Johnston P.G., Drake J.C., Trepel J., Allegra C.J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. 52:1992;4306-4312
58. Kihara C., Tsunoda T., Tanaka T., Yamana H., Furukawa Y., Ono K., et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 61:2001;6474-6479
59. Kinsella A.R., Smith D., Pickard M. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br. J. Cancer. 75:1997;935-945
60. Leppa S., Sistonen L. Heat shock response - pathophysiological implications. Ann. Med. 29:1997;73-78
61. Levsky J.M., Shenoy S.M., Pezo R.C., Singer R.H. Single-cell gene expression profiling. Science. 297:2002;836-840
62. Lindblad-Toh K., Winchester E., Daly M.J., Wang D.G., Hirschhorn J.N., Laviolette J.P., et al. Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse. Nat. Genet. 24:2000;381-386
63. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer. 3:2003;330-338
64. Ma X.J., Salunga R., Tuggle J.T., Gaudet J., Enright E., McQuary P., et al. Gene expression profiles of human breast cancer progression. Proc. Natl. Acad. Sci. USA. 100:2003;5974-5979
65. Machover D., Diaz-Rubio E., de Gramont A., Schilf A., Gastiaburu J.J., Brienza S., et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7:1996;95-98
66. Mariadason J.M., Arango D., Shi Q., Wilson A.J., Corner G.A., Nicholas C., et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 63:2003;8791-8812
67. Maxwell P.J., Longley D.B., Latif T., Boyer J., Allen W., Lynch M., et al. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res. 63:2003;4602-4606
68. Metzger R., Danenberg K., Leichman C.G., Salonga D., Schwartz E.L., Wadler S., et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res. 4:1998;2371-2376
69. Mirjolet J.F., Barberi-Heyob M., Merlin J.L., Marchal S., Etienne M.C., Milano G., Bey P. Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity. Br. J. Cancer. 78:1998;62-68
70. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Tangen C.M., et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med. 122:1995a;321-326
71. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Tangen C.M., et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J. Clin. Oncol. 13:1995b;2936-2943
72. Mori Y., Selaru F.M., Sato F., Yin J., Simms L.A., Xu Y., et al. The impact of microsatellite instability on the molecular phenotype of colorectal tumors. Cancer Res. 63:2003;4577-4582
73. Mori Y., Yin J., Sato F., Sterian A., Simms L.A., Selaru F.M., et al. Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res. 64:2004;2434-2438
74. Morin P.J. Drug resistance and the microenvironment: nature and nurture. Drug Resist. Update. 6:2003;169-172
75. Nita M.E., Nagawa H., Tominaga O., Tsuno N., Fujii S., Sasaki S., Fu C.G., Takenoue T., Tsuruo T., Muto T. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br. J. Cancer. 78:1998;986-992
76. Notterman D.A., Alon U., Sierk A.J., Levine A.J. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 61:2001;3124-3130
77. Novoradovskaya N., Whitfield M.L., Basehore L.S., Novoradovsky A., Pesich R., Usary J., et al. Universal Reference RNA as a standard for microarray experiments. BMC Genomics. 5:2004;20
78. Perou C.M., Jeffrey S.S., van de Rijn M., Rees C.A., Eisen M.B., Ross D.T., et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. USA. 96:1999;9212-9217
79. Pollack J.R., Sorlie T., Perou C.M., Rees C.A., Jeffrey S.S., Lonning P.E., Tibshirani R., Botstein D., Borresen-Dale A.L., Brown P.O. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl. Acad. Sci. USA. 99:2002;12963-12968
80. Pomeroy S.L., Tamayo P., Gaasenbeek M., Sturla L.M., Angelo M., McLaughlin M.E., et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 415:2002;436-442
81. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 275:1997;967-969
82. Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349:2003;247-257
83. Saha S., Bardelli A., Buckhaults P., Velculescu V.E., Rago C., St Croix B., et al. A phosphatase associated with metastasis of colorectal cancer. Science. 294:2001;1343-1346
84. Saito H., Tsujitani S., Oka S., Kondo A., Ikeguchi M., Maeta M., Kaibara N. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br. J. Cancer. 81:1999;484-489
85. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6:2000;1322-1327
86. Sarris M., Lee C.S. nm23 protein expression in colorectal carcinoma metastasis in regional lymph nodes and the liver. Eur. J. Surg. Oncol. 27:2001;170-174
87. Sax J.K., Fei P., Murphy M.E., Bernhard E., Korsmeyer S.J., El-Deiry W.S. BID regulation by p53 contributes to chemosensitivity. Nat. Cell Biol. 4:2002;842-849
88. Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O., Diehn M., et al. Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell. 14:2003;4376-4386
89. Scherf U., Ross D.T., Waltham M., Smith L.H., Lee J.K., Tanabe L., et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24:2000;236-244
90. Schwartz E.L., Baptiste N., Wadler S., Makower D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J. Biol. Chem. 270:1995;19073-19077
91. Selaru F.M., Xu Y., Yin J., Zou T., Liu T.C., Mori Y., et al. Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. Gastroenterology. 122:2002;606-613
92. Seoane J., Le H.V., Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 419:2002;729-734
93. Shannon B.A., Iacopetta B.J. Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features. Cancer Lett. 167:2001;91-97
94. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA. 98:2001;10869-10874
95. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., Kinzler K.W. Genes expressed in human tumor endothelium. Science. 289:2000;1197-1202
96. Stuart R.O., Wachsman W., Berry C.C., Wang-Rodriguez J., Wasserman L., Klacansky I., et al. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc. Natl. Acad. Sci. USA. 101:2004;615-620
97. Takahashi Y., Nagata T., Ishii Y., Ikarashi M., Ishikawa K., Asai S. Up-regulation of vitamin D3 up-regulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. Oncol. Rep. 9:2002;75-79
98. Tay S.T., Leong S.H., Yu K., Aggarwal A., Tan S.Y., Lee C.H., et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res. 63:2003;3309-3316
99. Van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:2002;1999-2009
100. Van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536
101. Vasilevskaya, I., O'Dwyer, P.J., 2003. Role of Jun and Jun kinase in resistance of cancer cells to therapy, 6: 147-156.
102. Violette S., Poulain L., Dussaulx E., Pepin D., Faussat A.M., Chambaz J., et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int. J. Cancer. 98:2002;498-504
103. Wang T.L., Diaz L.A. Jr., Romans K., Bardelli A., Saha S., Galizia G., et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc. Natl. Acad. Sci. USA. 101:2004;3089-3094
104. Wang W., Marsh S., Cassidy J., McLeod H.L. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res. 61:2001;5505-5510
105. Wilson A.J., Velcich A., Arango D., Kurland A.R., Shenoy S.M., Pezo R.C., Levsky J.M., Singer R.H., Augenlicht L.H. Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. 62:2002;6006-6010
106. Yan P.S., Perry M.R., Laux D.E., Asare A.L., Caldwell C.W., Huang T.H. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin. Cancer Res. 6:2000;1432-1438
107. Zembutsu H., Ohnishi Y., Tsunoda T., Furukawa Y., Katagiri T., Ueyama Y., et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 62:2002;518-527
108. Zhang L., Yu J., Park B.H., Kinzler K.W., Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science. 290:2000;989-992
109. Zou T.T., Selaru F.M., Xu Y., Shustova V., Yin J., Mori Y., et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene. 21:2002;4855-4862